GlassScriptPhysician profile
Brian Dennis Hoffman
NPI 1699756924
$1,571.01
in general payments reported to CMS, 2019-2025
19 companies · $256 in 2025
The $256 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.95 · 2021: $95.67 · 2022: $221 · 2023: $441 · 2024: $532 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,228.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $384.15 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $314.24 | 2021-2025 | |
| Pfizer INC. | $214.60 | 2022-2025 | |
| Glaxosmithkline, LLC. | $90.55 | 2021-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $67.52 | 2021-2023 | Mounjaro, Jardiance |
| Abbott Laboratories | $65.31 | 2022-2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $60.86 | 2024-2025 | Airsupra, Farxiga |
| Stryker Corporation | $48.00 | 2023 | Spinejack |
| Biohaven Pharmaceuticals, INC. | $46.01 | 2021 | |
| Exact Sciences Corporation | $44.05 | 2024-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $42.58 | 2024-2025 | Veozah |
| Regeneron Healthcare Solutions, INC. | $38.99 | 2025 | Libtayo |
| Dexcom, INC. | $33.32 | 2021-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $26.01 | 2022 | |
| Inari Medical, INC. | $24.70 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $24.25 | 2023 | Omni Hysteroscope |
| Merck Sharp & Dohme LLC | $16.18 | 2023 | Steglatro, Belsomra |
| Idorsia Pharmaceuticals US INC | $15.91 | 2023 | Quviviq |
| Amgen INC. | $13.78 | 2023 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.